Home

JOSEPH R III HYDE

CIK 903352 · Chairman · last filed 2019-01-03

JOSEPH R III HYDE is a Chairman who has filed 144 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider was granted $15.6K of GTXI on Jan 3, 2019. Across all open-market trades the lifetime net is +$24.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $264.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$264.40M

Companies

3

Total Filings

144

Lifetime Open-Market Net

$24.61M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Oncternal Therapeutics, Inc. (GTXI) Delisted Director 4,229,013 — — $24.61M 86 2019-01-03
AZO Director 73,930 $3064.48 $226.56M $0 50 2018-01-02
FDX Director 116,000 $326.20 $37.84M $0 8 2010-09-29

Recent Filings

144 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-01-03 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +18,168 $15.6K EDGAR
2018-10-02 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +10,416 $15.6K EDGAR
2018-07-03 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +1,010 $15.6K EDGAR
2018-04-03 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +894 $15.6K EDGAR
2018-01-04 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +1,363 $15.6K EDGAR
2018-01-02 AZO Grant (A) +302 $215.0K EDGAR
2017-12-14 AZO Exer (M) +3,000 $357.4K EDGAR
2017-10-04 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +1,967 $15.6K EDGAR
2017-10-02 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +1,130,582 $0 EDGAR
2017-07-05 Oncternal Therapeutics, Inc. (GTXI) Delisted Grant (A) +2,970 $15.6K EDGAR
Showing 1–10 of 144
Page 1 of 15
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.